Oruka Therapeutics SVP sells $1.05M in shares

Oruka Therapeutics' Senior Vice President of Finance, Arjun Agarwal, sold $1.05 million worth of the company's common stock on November 12, 2026, as part of a pre-arranged Rule 10b5-1 trading plan. The shares were sold at prices between $101.28 and $107.0 per share, with the stock currently trading at $105.35, near its 52-week high.

Agarwal also acquired 10,000 shares through employee stock options, totaling approximately $156,915. The company has recently reported positive clinical trial data for its psoriasis treatment, ORKA-001, which has received renewed interest from analysts despite a decline in stock price.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.